David Osei-Bonsu

Pharma speaker programs face four overlapping legal regimes and sustained enforcement scrutiny.

FDA finally clarified how drugmakers can share cost data with insurers and formulary committees.

Recent rulings narrow brand teams' legal defenses for patient assistance program involvement.

Insurers' PA promises face scrutiny as denial data becomes public.

Specialty pharmacy brands need different value-based contract messaging than traditional pharma.

The FDA is now enforcing drug-promotion rules on social media platforms it long ignored.